Brii Biosciences (stock code: 2137.HK) is a biotechnology company developing therapies to address some of the world's most common public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice.
Currency | HKD |
Previous Close | 1.00 |
Change (%) | -1.96 |
Volume | 248,500 |
Number of Shares(mil) | 729.99 |
Share Market Cap (mil) | 729.99 |
Indication | Program | Preclinical | IND | Phase 1 | Phase 2 | Phase 3 | NDA/BLA | Commercial | Brii Rights | Partners |
Hepatitis B
Treatment(1)
Prevention
|
BRII-179 |
|
Global | ![]() |
||||||
BRII-835 (Elebsiran) (2) |
|
Greater China* | ![]() |
|||||||
BRII-877 (Tobevibart) (3) | Greater China* | ![]() |
||||||||
PreHevbriTM(4) |
|
APAC ex-Japan | ![]() |
|||||||
HIV |
BRII-732 |
|
Global | Internally discovered |
||||||
BRII-753 |
|
Global | Internally discovered |
|||||||
MDR/XDR
Gram-negative Bacterial Infections |
||||||||||
BRII-693 |
|
Greater China* | Monash University | |||||||
NTM Lung Disease |
BRII-658 (Epetraborole) (5) |
|
Greater China* | ![]() |
Indication | Program | Preclinical | IND | Phase 1 | Phase 2 | Phase 3 | NDA/BLA | Commercial | Brii Rights | Partners |
PPD |
BRII-296 |
|
Global |
Internally discovered |
||||||
Anxiety &
Depressive Disorder |
BRII-297 |
|
Global |
Internally discovered |
* Greater China – Mainland China, Macau, Hong Kong and Taiwan |
Audit and Risk Committee |
Nomination Committee |
Remuneration Committee |
Strategic Committee |
Executive Directors |
Non-executive Directors |
Independent Non-executive Directors |
|
---|---|---|---|---|---|---|---|
Dr. Zhi Hong |
![]() |
![]() |
|||||
Dr. Ankang Li |
![]() |
![]() |
|||||
Dr. Martin J. Murphy Jr. |
![]() |
![]() |
![]() |
||||
Ms. Grace Hui Tang |
![]() |
![]() |
![]() |
||||
Mr. Yiu Wa Alec Tsui |
![]() |
![]() |
![]() |
||||
Mr. Gregg Huber Alton |
![]() |
![]() |
![]() |
||||
Dr. Taiyin Yang |
![]() |
![]() |
![]() |
Susannah Cantrell, Ph.D.
Chief Business Officer
Eleanor (Ellee) de Groot, Ph.D.
Chief Technology Officer
Zhi Hong, Ph.D.
Executive Director
Chairman of the Board and Chief Executive Officer
Brian Alvin Johns, Ph.D.
Chief Scientific Officer
Ankang Li, Ph.D., J.D., CFA
Executive Director, Chief Strategy and Financial Officer
Chief Executive Officer of TSB Therapeutics
David Margolis, M.D., MPH
Chief Medical Officer
Karen D. Neuendorff
Chief People Officer and Head of Human Resources
Qing Zhu, Ph.D.
Head of China R&D
BRII-B (RMB'000) | 2021 | 2022 | 2023 |
---|---|---|---|
Operating Results | |||
Other income | 99,032 | 107,857 | 163,728 |
Other gains and losses | 45,062 | (12,289) | 252,402 |
Research and development expenses | (494,615) | (440,634) | (402,705) |
Administrative expenses | (208,404) | (168,629) | (196,499) |
Fair value loss on financial liabilities at FVTPL | (3,598,847) | - | - |
Finance costs | (1,175) | (851) | (494) |
Listing expenses | (32,137) | - | - |
Loss for the year | (4,191,084) | (489,781) | (184,370) |
Financial Position | |||
Total assets | 3,611,699 | 3,391,849 | 3,198,251 |
Total liabilities | 300,443 | 234,352 | 125,869 |
Total equity (deficits) | 3,311,256 | 3,157,497 | 3,072,382 |
Selected Items from Consolidated Cash Flow Statement | |||
Net cash used in operating activities | (879,457) | (496,279) | (594,014) |
Net cash used in investing activities | (475,756) | (1,433,168) | (104,350) |
Net cash from financing activities | 3,230,134 | (3,042) | (10,977) |
Net increase in cash and cash equivalents | 1,874,921 | (1,932,489) | (709,341) |
Cash and cash equivalents at end of the year | 2,855,093 | 1,190,572 | 489,650 |
Key indicators | |||
Loss per share - Basic and diluted (RMB) | (9.48) | (0.67) | (0.24) |
Current Ratio | 1.22 | 1.34 | 2.21 |